Triple
T20301132
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Imfinzi |
E505480
|
entity |
| Predicate | hasMolecularTarget |
P37016
|
FINISHED |
| Object | B7-H1 |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: B7-H1 | Statement: [Imfinzi, hasMolecularTarget, B7-H1]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: B7-H1 Context triple: [Imfinzi, hasMolecularTarget, B7-H1]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
E.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: B7-H1 Target entity description: B7-H1, also known as PD-L1, is an immune checkpoint protein expressed on various cells that modulates T-cell activity and is targeted by certain cancer immunotherapies.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
E.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b4b8ab648190906e18538c250148 |
completed | April 16, 2026, 10:06 a.m. |
| NER | Named-entity recognition | batch_69e6770c700c81909da247cef0d0f1eb |
completed | April 20, 2026, 6:57 p.m. |
Created at: April 16, 2026, 11:17 a.m.